Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 171

1.

Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome.

Engler DA, Gupta S, Growdon WB, Drapkin RI, Nitta M, Sergent PA, Allred SF, Gross J, Deavers MT, Kuo WL, Karlan BY, Rueda BR, Orsulic S, Gershenson DM, Birrer MJ, Gray JW, Mohapatra G.

PLoS One. 2012;7(2):e30996. doi: 10.1371/journal.pone.0030996. Epub 2012 Feb 15.

PMID:
22355333
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis.

Espinosa I, Catasus L, Canet B, D'Angelo E, Muñoz J, Prat J.

Mod Pathol. 2011 Jun;24(6):846-54. doi: 10.1038/modpathol.2011.12. Epub 2011 Feb 11.

PMID:
21317880
[PubMed - indexed for MEDLINE]
Free Article
3.

High levels of genomic aberrations in serous ovarian cancers are associated with better survival.

Baumbusch LO, Helland Å, Wang Y, Liestøl K, Schaner ME, Holm R, Etemadmoghadam D, Alsop K, Brown P; Australian Ovarian Cancer Study Group, Mitchell G, Fereday S, DeFazio A, Bowtell DD, Kristensen GB, Lingjærde OC, Børresen-Dale AL.

PLoS One. 2013;8(1):e54356. doi: 10.1371/journal.pone.0054356. Epub 2013 Jan 23.

PMID:
23372714
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.

Karlan BY, Dering J, Walsh C, Orsulic S, Lester J, Anderson LA, Ginther CL, Fejzo M, Slamon D.

Gynecol Oncol. 2014 Feb;132(2):334-42. doi: 10.1016/j.ygyno.2013.12.021. Epub 2013 Dec 22.

PMID:
24368280
[PubMed - indexed for MEDLINE]
5.

A distinctive ovarian cancer molecular subgroup characterized by poor prognosis and somatic focal copy number amplifications at chromosome 19.

Sung CO, Song IH, Sohn I.

Gynecol Oncol. 2014 Feb;132(2):343-50. doi: 10.1016/j.ygyno.2013.11.036. Epub 2013 Dec 8.

PMID:
24321399
[PubMed - indexed for MEDLINE]
6.

Molecular clustering based on ERα and EIG121 predicts survival in high-grade serous carcinoma of the ovary/peritoneum.

Schlumbrecht MP, Xie SS, Shipley GL, Urbauer DL, Broaddus RR.

Mod Pathol. 2011 Mar;24(3):453-62. doi: 10.1038/modpathol.2010.211. Epub 2010 Nov 19.

PMID:
21102415
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Gene expression patterns that characterize advanced stage serous ovarian cancers.

Lancaster JM, Dressman HK, Whitaker RS, Havrilesky L, Gray J, Marks JR, Nevins JR, Berchuck A.

J Soc Gynecol Investig. 2004 Jan;11(1):51-9.

PMID:
14706684
[PubMed - indexed for MEDLINE]
8.

Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer.

Chien J, Fan JB, Bell DA, April C, Klotzle B, Ota T, Lingle WL, Gonzalez Bosquet J, Shridhar V, Hartmann LC.

Gynecol Oncol. 2009 Jul;114(1):3-11. doi: 10.1016/j.ygyno.2009.04.002. Epub 2009 May 1.

PMID:
19410283
[PubMed - indexed for MEDLINE]
9.

Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome.

Wang ZC, Birkbak NJ, Culhane AC, Drapkin R, Fatima A, Tian R, Schwede M, Alsop K, Daniels KE, Piao H, Liu J, Etemadmoghadam D, Miron A, Salvesen HB, Mitchell G, DeFazio A, Quackenbush J, Berkowitz RS, Iglehart JD, Bowtell DD; Australian Ovarian Cancer Study Group, Matulonis UA.

Clin Cancer Res. 2012 Oct 15;18(20):5806-15. doi: 10.1158/1078-0432.CCR-12-0857. Epub 2012 Aug 21.

PMID:
22912389
[PubMed - indexed for MEDLINE]
Free Article
10.

Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas.

Kuo KT, Guan B, Feng Y, Mao TL, Chen X, Jinawath N, Wang Y, Kurman RJ, Shih IeM, Wang TL.

Cancer Res. 2009 May 1;69(9):4036-42. doi: 10.1158/0008-5472.CAN-08-3913. Epub 2009 Apr 21. Erratum in: Cancer Res. 2009 Jun 15;69(12):5267.

PMID:
19383911
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer.

Dai W, Zeller C, Masrour N, Siddiqui N, Paul J, Brown R.

Clin Cancer Res. 2013 Oct 15;19(20):5788-97. doi: 10.1158/1078-0432.CCR-13-1217. Epub 2013 Aug 21.

PMID:
23965899
[PubMed - indexed for MEDLINE]
12.

Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma.

Tang Z, Ow GS, Thiery JP, Ivshina AV, Kuznetsov VA.

Int J Cancer. 2014 Jan 15;134(2):306-18. doi: 10.1002/ijc.28371. Epub 2013 Aug 7.

PMID:
23825028
[PubMed - indexed for MEDLINE]
13.

Predictive modeling using a somatic mutational profile in ovarian high grade serous carcinoma.

Sohn I, Sung CO.

PLoS One. 2013;8(1):e54089. doi: 10.1371/journal.pone.0054089. Epub 2013 Jan 10.

PMID:
23326577
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays.

Mayr D, Kanitz V, Anderegg B, Luthardt B, Engel J, Löhrs U, Amann G, Diebold J.

Am J Clin Pathol. 2006 Jul;126(1):101-9.

PMID:
16753589
[PubMed - indexed for MEDLINE]
Free Article
15.

High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer.

Staaf J, Jönsson G, Ringnér M, Vallon-Christersson J, Grabau D, Arason A, Gunnarsson H, Agnarsson BA, Malmström PO, Johannsson OT, Loman N, Barkardottir RB, Borg A.

Breast Cancer Res. 2010;12(3):R25. doi: 10.1186/bcr2568. Epub 2010 May 6.

PMID:
20459607
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas.

Osterberg L, Levan K, Partheen K, Delle U, Olsson B, Sundfeldt K, Horvath G.

BMC Cancer. 2009 Oct 18;9:368. doi: 10.1186/1471-2407-9-368.

PMID:
19835627
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival.

Pieretti M, Hopenhayn-Rich C, Khattar NH, Cao Y, Huang B, Tucker TC.

Cancer Invest. 2002;20(1):11-23.

PMID:
11852993
[PubMed - indexed for MEDLINE]
18.

Analysis of chromosomal changes in serous ovarian carcinoma using high-resolution array comparative genomic hybridization: Potential predictive markers of chemoresistant disease.

Kim SW, Kim JW, Kim YT, Kim JH, Kim S, Yoon BS, Nam EJ, Kim HY.

Genes Chromosomes Cancer. 2007 Jan;46(1):1-9.

PMID:
17044060
[PubMed - indexed for MEDLINE]
19.

Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.

Madore J, Ren F, Filali-Mouhim A, Sanchez L, Köbel M, Tonin PN, Huntsman D, Provencher DM, Mes-Masson AM.

J Pathol. 2010 Feb;220(3):392-400. doi: 10.1002/path.2659.

PMID:
19967725
[PubMed - indexed for MEDLINE]
20.

Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas.

Têtu B, Popa I, Bairati I, L'Esperance S, Bachvarova M, Plante M, Harel F, Bachvarov D.

Mod Pathol. 2008 Aug;21(8):1002-10. doi: 10.1038/modpathol.2008.80. Epub 2008 May 23.

PMID:
18500265
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk